Drug Trial Radar · NCT01343277
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma
Last checked: Nov 19, 2026Latest source record: Aug 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
579
Actual
Start
Jun 2011
Primary completion
Jan 2015
Study completion Apr 2016
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- PharmaMar
- First posted
- Apr 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate whether overall survival for the trabectedin group is superior to the dacarbazine group for patients with advanced L-sarcoma (liposarcoma or leiomyosarcoma).
Conditions
- Advanced Liposarcoma or Leiomyosarcoma
Interventions
TrabectedinDrug
Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
DacarbazineDrug
Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: approximately 3 years 8 months (From Study start date [27 May 2011] up to final analysis data cut-off [05 January 2015]
Locations
88 sites in 4 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
Santa Monica, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Hartford, Connecticut
Site not named
New Haven, Connecticut
Site not named
Boynton Beach, Florida
Site not named
Hollywood, Florida
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Savannah, Georgia
Site not named
Post Falls, Idaho
Site not named
Chicago, Illinois
Site not named
Naperville, Illinois
Site not named
Park Ridge, Illinois
Site not named
Peoria, Illinois
Site not named
Springfield, Illinois
Site not named
Indianapolis, Indiana
Site not named
Iowa City, Iowa
Site not named
Sioux City, Iowa
Site not named
Overland Park, Kansas
Site not named
Wichita, Kansas
Site not named
Louisville, Kentucky
Site not named
Covington, Louisiana
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Ann Arbor, Michigan
Site not named
Detroit, Michigan
Site not named
Lansing, Michigan
Site not named
Jackson, Mississippi
Site not named
Saint Joseph, Missouri
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.